Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics

Carlin JB (2002) Assessing the homogeneity of three odds ratios: A case study in small- sample inference. In: Gatsonis C, Robert EK, Carlin B, Carriquiry A, Gelman A, Verdinelli I, West M (eds) Case studies in Bayesian statistics, vol V. Springer, New York, pp 279–290

Cheung YK, Chappell R (2000) Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56:1177–1182

Choi YK, Johnson WO, Collins MT, Gardner IA (2006) Bayesian inferences for receiver operating characteristic curves in the absence of a gold standard. J Agric Biol Environ Stat 11:210–229

Congdon P (2003) Applied Bayesian modelling. Wiley, Chichester

Elkind MS, Sacco RL, MacArthur RB, Fink DJ, Peerschke E, Andrews H, Neils G, Stillman J, Corporan T, Leifer D, Cheung K (2008) The neuroprotection with statin therapy for acute recovery trial (NeuSTART): An adaptive design phase i dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int J Stroke 3:210–218

Gelman A, Carlin JB, Stern HS, Rubin DB (2004) Bayesian data analysis, 2nd edn. Chapman and Hall/CRC, New York

Morita S, Thall PF, Müller P (2008) Determining the effective sample size of a parametric prior. Biometrics 64:595–602

Morita S, Thall PF, Müller P (2009) Prior effective sample size in conditionally independent hierarchical models. Technical Report, Yokohama City University

O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46:33–48

Thall PF, Cook JD (2004) Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60:684–693

Thall PF, Wooten LH, Tannir NM (2005) Monitoring event times in early phase clinical trials: Some practical issues. Clin Trials 2:467–478